Advances in Psoriasis Biological Agent
DOI:
https://doi.org/10.37275/arkus.v5i1.76Keywords:
Psoriasis, Pathogenesis, Antibody, Antigen, Immune SystemAbstract
Biological agents are proteins that have pharmacological activity, derived from living materials, either from humans, animals, or microorganisms, and can be synthesized in large quantities with the help of genetic engineering techniques (recombinant DNA techniques). Biological agents are divided into three types: monoclonal antibodies in humanized, primatized, fully human, chimeric; cytokines or recombinant human cytokines growth factors; and 3) fusion proteins. The nomenclature for receptor fusion proteins and monoclonal antibodies follows the rules established by the International Nonproprietary Names of the World Health Organization (WHO). The suffix "-cept" is used as a code to identify a drug as a receptor molecule, and "-mab" is used as a code for a monoclonal antibody. The origin of the antibody is indicated by the code "-u-" for fully human origin (e.g., secukinumab). Antibodies derived from humans and mice are humanized, code named "-Zu-" (e.g., ixekizumab or chimeric, "-xi-" (eg, infliximab).
Authors
- Nopriyati1*
- Reza Mayasari1
- 1Department of Dermatology and Venereology, Faculty of Medicine, Unibversitas Sriwijaya, Palembang, Indonesia
Corresponding author Nopriyati — nopriyati@gmail.com
Downloads
Published
Issue
Section
License
Authors retain copyright and grant Arkus the right of first publication. Published articles are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0). This license permits sharing and adaptation for non-commercial purposes, provided appropriate attribution is given and adaptations are distributed under the same license. Official license: https://creativecommons.org/licenses/by-nc-sa/4.0/.
How to Cite
Article Metrics
Views and downloads recorded by this journal.